ORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Or

Kahn Swick & Foti, LLC is reminding investors who purchased Organon & Co. (OGN) securities between October 31, 2024, and April 30, 2025, that they have until July 22, 2025, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that Organon failed to disclose material information regarding its dividend payout, which was reset from $0.28 to $0.02 per share, contradicting prior assurances and causing the stock price to fall over 27% on May 1, 2025.

Analysis

A securities class action lawsuit has been initiated against Organon & Co. (NYSE: OGN), with investors who purchased securities between October 31, 2024, and April 30, 2025, having until July 22, 2025, to file for lead plaintiff status. The lawsuit, Hauser V. Organon & Co., et al., No. 25-cv-05322, pending in the U.S. District Court for the District of New Jersey, alleges that Organon and certain executives violated federal securities laws by failing to disclose material information. Specifically, the company announced on March 10, 2025, a drastic reduction in its quarterly dividend from $0.28 to $0.02 per share. This action directly contradicted previous management assurances that the dividend was a "number one priority" and that the company was committed to its existing capital allocation strategy. Following this news, Organon's share price experienced a significant decline of over 27%, falling from a closing price of $12.93 on April 30, 2025, to $9.45 on May 1, 2025. This event has triggered strongly negative sentiment (overall score -0.75, OGN-specific -0.8) and a cautious tone, reflecting concerns over company fundamentals, capital return policies, and management credibility, all central themes highlighted by this litigation.

Key Decisions for Investors

• Investors who acquired Organon & Co. securities between October 31, 2024, and April 30, 2025, should assess their eligibility and consider contacting the involved law firm by the July 22, 2025 deadline to understand their rights concerning potential recovery for economic losses.
• Current and prospective investors in OGN should exercise significant caution due to the ongoing class action lawsuit, the substantial stock price drop, and the serious questions raised about management's transparency and commitment to its stated capital allocation policies.
• Closely monitor developments in the securities litigation and any further communications from Organon regarding its dividend strategy and financial outlook, as these will be crucial for gauging future stock performance and investor trust.
• Given the severe dividend cut and subsequent share price collapse, a thorough reassessment of Organon's investment thesis is warranted, acknowledging the heightened risk profile and negative market sentiment.